Skip to main content
SpringerLink
Log in

Cost-Effectiveness Analysis Alongside Clinical Trials

Statistical and Methodological Issues

  • Chapter
Cardiovascular Health Care Economics

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 379 Accesses

Abstract

Over the past quarter century, as costs have become an important factor in medical decision making, indices of cost-effectiveness (CE) have increasingly been used in the evaluation of medical therapies. The traditional approach to cost-effectiveness analysis (CEA) utilizes decision-analytic models based on estimates of cost and effectiveness outcomes obtained from nonsampled secondary data (from the literature, insurance claims databases, and expert opinion) and employs sensitivity analysis to examine the variability in results as uncertain model inputs are varied over reasonable ranges. Throughout the past decade, there has been an increasing trend for economic studies to be incorporated into large clinical trials. This has allowed for cost-effectiveness to be evaluated directly, using primary patient-level data on both clinical outcomes and costs. The stochastic, or random, nature of this data, resulting from patient-to-patient (sampling) variability, allows for uncertainty associated with estimates of cost-effectiveness to be estimated using methods of statistical analysis. This chapter presents an overview of statistical and other methodological considerations in the evaluation of cost-effectiveness using experimentally obtained data from randomized controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19: 3219–3236.

    Article  PubMed  CAS  Google Scholar 

  2. Kendall MG, S., A., The advanced theory of statistics. Volume I: Distribution Theory. Charles Griffin ( 110 ) Company Limited, London, 1969.

    Google Scholar 

  3. Efron B. Bootstrap methods: another look at the Jackknife. Ann Stat 1979; 7: 1–26.

    Article  Google Scholar 

  4. Efron B. Non-parametric standard errors and confidence intervals (with discussion). Canadian J Stat 1981; 9: 139–172.

    Article  Google Scholar 

  5. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc 1987; 82: 171–200.

    Article  Google Scholar 

  6. Altman DG, Bland JM. Absence of evidence is not evidence of absense. Br Med J 1995; 311: 485.

    Article  CAS  Google Scholar 

  7. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78: 605–610.

    Article  Google Scholar 

  8. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461–494.

    Article  PubMed  CAS  Google Scholar 

  9. Kalbfleisch JG. Probability and statistical inference. Volume 1: Probability. Springer texts in statistics, vol. 1. Springer-Verlag, New York, 1985, p. 343.

    Google Scholar 

  10. Cox DR, Hinkley DV. Theoretical Statistics. Chapman and Hall, New York, 1986.

    Google Scholar 

  11. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212–224.

    Article  PubMed  CAS  Google Scholar 

  12. Briggs A, Fenn P. Trying to do better than average: a commentary on `statistical inference for cost-effectiveness ratios’. Health Econ 1997; 6: 491–495.

    Article  PubMed  CAS  Google Scholar 

  13. O’Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150–163.

    Article  PubMed  Google Scholar 

  14. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723–740.

    Article  PubMed  CAS  Google Scholar 

  15. Fieller EC. The distribution of an index in a normal bivariate population. Biometrika 1932; 56: 635–639.

    Google Scholar 

  16. Fieller EC. Some problems in interval estimation. J Royal Stat Society, Series B, 1954; 16: 175–183.

    Google Scholar 

  17. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996; 15: 1447–1458.

    Article  PubMed  CAS  Google Scholar 

  18. Willan AR, O’Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller’s theorem. Health Econ 1996; 5: 297–305.

    Article  PubMed  CAS  Google Scholar 

  19. Briggs AH, O’Brien BJ, Blackhouse G. Thinking Outside the Box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377–401.

    Article  PubMed  Google Scholar 

  20. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat Med 1999; 18: 3245–3262.

    Article  PubMed  CAS  Google Scholar 

  21. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327–340.

    Article  PubMed  CAS  Google Scholar 

  22. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243–252.

    Article  PubMed  CAS  Google Scholar 

  23. Glick HA, Polsky D. Assessing the uncertainty of the results of randomized controlled trials. In: Society for Medical Decision Making, Short Course #5: Prospective Economic Evaluation of Clinical Trials: Methods and Analysis, course handouts, Reno, NV, 1999.

    Google Scholar 

  24. Stinnett AA, Mullahy J. The negative side of cost-effectiveness analysis. JAMA 1997; 277: 1931–1933.

    Article  PubMed  CAS  Google Scholar 

  25. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl): 568–580.

    Article  Google Scholar 

  26. Heitjan DF, Moskowitz AJ, Whang W. Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making 1999; 19: 9–15.

    Article  PubMed  CAS  Google Scholar 

  27. Scharfstein JA. Cost-Effectiveness and AIDS: Methods and Application. Doctoral thesis. Harvard University, Boston, MA, 1997.

    Google Scholar 

  28. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive versus conservative strategy for the treatment of unstable angina and non-ST elevation myocardial infarction. JAMA 2002; 288: 1851–1858.

    Article  PubMed  Google Scholar 

  29. Cook JR, Heyse JF. Use of an angular transformation for ratio estimation in cost-effectiveness analysis. Stat Med 2000; 19: 2989–3003.

    Article  PubMed  CAS  Google Scholar 

  30. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293–1301.

    Article  PubMed  CAS  Google Scholar 

  31. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309–319.

    Google Scholar 

  32. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14: 467–471.

    Article  PubMed  CAS  Google Scholar 

  33. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1999; 8: 191–201.

    Article  PubMed  CAS  Google Scholar 

  34. Heitjan DF. Fieller’s method and net health benefits. Health Econ 2000; 9: 327–335.

    Article  PubMed  CAS  Google Scholar 

  35. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making 1998; 18 (2 Suppl): S81 - S92.

    Article  PubMed  CAS  Google Scholar 

  36. Willan AR, O’Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203–211.

    Article  PubMed  CAS  Google Scholar 

  37. Gardiner JC, Huebner M, Jetton J, Bradley O. Power and sample assessments for tests of hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227–234.

    Article  PubMed  CAS  Google Scholar 

  38. Al MJ, van Hout BA, Michel BC, Rutten FF. Sample size calculation in economic evaluations. Health Econ 1998; 7: 327–335.

    Article  PubMed  CAS  Google Scholar 

  39. Laska EM, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Med Decis Making 1999; 19: 339–343.

    Article  PubMed  CAS  Google Scholar 

  40. Briggs A. Economics notes: handling uncertainty in economic evaluation. Br Med J 1999; 319: 120.

    Article  CAS  Google Scholar 

  41. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623–630.

    Article  PubMed  CAS  Google Scholar 

  42. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257–261.

    Article  PubMed  CAS  Google Scholar 

  43. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. Int J Technol Assess Health Care 2001; 17: 69–82.

    Article  PubMed  CAS  Google Scholar 

  44. Briggs A, Gray A. Using cost effectiveness information. Br Med J 2000; 320: 246.

    Article  CAS  Google Scholar 

  45. Weintraub WS, Thompson TD, Culler S, et al. Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. Circulation 2000; 102: 392–398.

    Article  PubMed  CAS  Google Scholar 

  46. Mahoney EM, Thompson TD, Veledar E, et al. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation. J Am Coll Cardiol 2002; 40: 737–745.

    Article  PubMed  Google Scholar 

  47. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11: 415–430.

    Article  PubMed  Google Scholar 

  48. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253–1258.

    Article  PubMed  CAS  Google Scholar 

  49. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887.

    Article  PubMed  CAS  Google Scholar 

  50. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–338.

    Article  PubMed  CAS  Google Scholar 

  51. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419–458.

    Article  PubMed  CAS  Google Scholar 

  52. Kuntz KM, Weinstein MC. Modeling in economic evaluation. In: Drummond M, McGuire A (eds.), Economic Evaluation in Health Care: Merging Theory with Practice. Oxford University Press, Inc., NY, 2001, pp. 141–171.

    Google Scholar 

  53. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5: 157–177.

    Article  PubMed  CAS  Google Scholar 

  54. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. Br Med J 1999; 319: 635–638.

    Article  CAS  Google Scholar 

  55. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–466.

    Article  PubMed  CAS  Google Scholar 

  56. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366–371.

    Article  PubMed  CAS  Google Scholar 

  57. Mark DB, Lee TH. Conservative management of acute coronary syndrome: cheaper and better for you? Circulation 2002; 105: 666–668.

    PubMed  Google Scholar 

  58. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481–493.

    Article  PubMed  CAS  Google Scholar 

  59. Drummond MF, Bloom BS, Canin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671–682.

    Article  PubMed  CAS  Google Scholar 

  60. Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond A (ed.), Economic Evaluation in Health Care. Oxford University Press Inc., NY, 2001, pp. 256–276.

    Google Scholar 

  61. Jonsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. Int J Technol Assess Health Care 1997; 13: 49–58.

    Article  CAS  Google Scholar 

  62. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481–493.

    Article  PubMed  CAS  Google Scholar 

  63. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473–481.

    CAS  Google Scholar 

  64. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332–342.

    Article  PubMed  CAS  Google Scholar 

  65. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Elizabeth M. Mahoney ScD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haitao Chu MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

    William S. Weintraub MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mahoney, E.M., Chu, H. (2003). Cost-Effectiveness Analysis Alongside Clinical Trials. In: Weintraub, W.S. (eds) Cardiovascular Health Care Economics. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-398-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-398-9_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9784-7

  • Online ISBN: 978-1-59259-398-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation